About Pernix Therapeutics (NASDAQ:PTX)
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. Its products include Treximet, indicated for acute migraine; Zohydro ER with BeadTek, an extended-release opioid agonist indicated for the management of pain severe; Silenor for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla for major depressive disorder. It promotes selected non-core branded products, such as its cough and cold products, through co-promotion arrangements with third-party sales organizations, and distributes its generic products through its subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PTX
CUSIP71426V10
Phone800-793-2145
Debt
Debt-to-Equity Ratio-1.61%
Current Ratio1.00%
Quick Ratio0.94%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$146.07 million
Price / Sales0.19
Cash FlowN/A
Price / CashN/A
Book Value($14.77) per share
Price / Book-0.16
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-77,140,000.00
Net Margins-52.81%
Return on EquityN/A
Return on Assets-39.22%
Miscellaneous
Employees171
Outstanding Shares11,870,000
Pernix Therapeutics (NASDAQ:PTX) Frequently Asked Questions
What is Pernix Therapeutics' stock symbol?
Pernix Therapeutics trades on the NASDAQ under the ticker symbol "PTX."
How were Pernix Therapeutics' earnings last quarter?
Pernix Therapeutics Holdings (NASDAQ:PTX) posted its earnings results on Thursday, March, 8th. The specialty pharmaceutical company reported ($2.78) EPS for the quarter. The specialty pharmaceutical company earned $41.54 million during the quarter. View Pernix Therapeutics' Earnings History.
When is Pernix Therapeutics' next earnings date?
Who are some of Pernix Therapeutics' key competitors?
Some companies that are related to Pernix Therapeutics include Merrimack Pharmaceuticals (MACK), Chembio Diagnostics (CEMI), OncoMed Pharmaceuticals (OMED), Oramed Pharmaceuticals (ORMP), CytoDyn (CYDY), Alpine Immune Sciences (ALPN), RedHill Biopharma (RDHL), Conatus Pharmaceuticals (CNAT), Cumberland Pharmaceuticals (CPIX), KalVista Pharmaceuticals (KALV), Sunesis Pharmaceuticals (SNSS), Leap Therapeutics (LPTX), Flex Pharma (FLKS), Columbia Laboratories (JNP) and Ophthotech (OPHT).
Who are Pernix Therapeutics' key executives?
Pernix Therapeutics' management team includes the folowing people:
- John A. Sedor, Chairman of the Board, Chief Executive Officer (Age 72)
- Angus Smith, Senior Vice President, Chief Business Officer and Principal Financial Officer
- Kenneth Robert Pina, Senior Vice President, Chief Compliance Officer, General Counsel (Age 59)
- Glenn Whaley, Interim Vice President - Finance, Principal Accounting Officer, Corporate Controller (Age 49)
- John R. Leone, Lead Independent Director (Age 68)
- Douglas J. Swirsky, Director (Age 48)
- Dennis H. Langer M.D. J.D., Independent Director (Age 66)
- Gabriel S. Leung, Independent Director (Age 55)
Has Pernix Therapeutics been receiving favorable news coverage?
Headlines about PTX stock have been trending somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Pernix Therapeutics earned a media sentiment score of 0.13 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 47.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Pernix Therapeutics?
Shares of PTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pernix Therapeutics' stock price today?
One share of PTX stock can currently be purchased for approximately $2.33.
How big of a company is Pernix Therapeutics?
Pernix Therapeutics has a market capitalization of $28.02 million and generates $146.07 million in revenue each year. Pernix Therapeutics employs 171 workers across the globe.
How can I contact Pernix Therapeutics?
Pernix Therapeutics' mailing address is 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960. The specialty pharmaceutical company can be reached via phone at 800-793-2145 or via email at [email protected]
MarketBeat Community Rating for Pernix Therapeutics (PTX)
MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics and other stocks. Vote "Outperform" if you believe PTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Pernix Therapeutics (NASDAQ:PTX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | N/A |
| Consensus Rating Score: | N/A | N/A | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Pernix Therapeutics (NASDAQ:PTX) Consensus Price Target History
Pernix Therapeutics (NASDAQ:PTX) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/12/2016 | Brean Capital | Downgrade | Buy -> Hold | | N/A |  |
(Data available from 4/25/2016 forward)
Pernix Therapeutics (NASDAQ:PTX) Earnings History and Estimates Chart
Pernix Therapeutics (NASDAQ PTX) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/14/2018 | | | | | | | N/A | |
| 3/8/2018 | Q4 2017 | | ($2.78) | | $41.54 million | View | N/A | |
| 11/7/2017 | Q3 2017 | | ($0.57) | | $40.47 million | View | N/A | |
| 7/27/2017 | Q2 2017 | ($4.40) | ($2.16) | | $34.32 million | View | N/A | |
| 5/15/2017 | Q1 2017 | ($4.80) | ($2.94) | | $29.74 million | View | N/A | |
| 3/28/2017 | Q4 2016 | | ($3.86) | | $30.17 million | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.60) | ($2.99) | $48.60 million | $41.50 million | View | N/A | |
| 8/11/2016 | Q2 | ($0.08) | ($0.47) | $46.98 million | $36.75 million | View | Listen | |
| 5/5/2016 | Q116 | ($0.06) | ($0.42) | $44.55 million | $32.50 million | View | N/A | |
| 3/10/2016 | Q4 | $0.01 | ($0.59) | $47.95 million | $46.37 million | View | Listen | |
| 11/5/2015 | Q315 | $0.01 | $0.08 | $46.83 million | $48.60 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.01) | ($0.10) | $50.70 million | $47.00 million | View | N/A | |
| 5/1/2015 | Q115 | $0.04 | ($0.11) | $34.55 million | $33.90 million | View | N/A | |
| 2/25/2015 | Q414 | $0.18 | $0.25 | $52.70 million | $53.00 million | View | N/A | |
| 11/10/2014 | Q314 | | ($0.02) | $28.10 million | $31.50 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.05) | ($0.16) | $26.20 million | $17.40 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.05) | ($0.26) | $23.65 million | $19.10 million | View | N/A | |
| 3/17/2014 | Q413 | ($0.10) | ($0.15) | $23.82 million | $23.90 million | View | N/A | |
| 11/12/2013 | Q3 | ($0.1250) | ($0.16) | $23.06 million | $18.30 million | View | Listen | |
| 8/9/2013 | Q2 2013 | ($0.13) | ($0.16) | $20.82 million | $20.60 million | View | N/A | |
| 5/10/2013 | Q1 2013 | $0.02 | ($0.05) | $27.56 million | $22.08 million | View | N/A | |
| 3/18/2013 | Q4 2012 | $0.60 | ($0.30) | | | View | N/A | |
| 11/14/2012 | Q312 | $0.03 | ($0.01) | $15.04 million | $18.10 million | View | N/A | |
| 8/14/2012 | Q2 2012 | $0.10 | ($0.33) | | | View | N/A | |
| 5/15/2012 | Q1 2012 | $0.90 | $0.45 | | | View | N/A | |
| 3/28/2012 | Q4 2011 | $1.40 | $1.61 | | | View | N/A | |
| 11/15/2011 | Q3 2011 | $0.60 | $0.79 | | | View | N/A | |
| 8/16/2011 | Q2 2011 | $0.40 | $0.65 | | | View | N/A | |
| 5/17/2011 | Q1 2011 | $1.20 | $0.68 | | | View | N/A | |
| 3/31/2011 | Q4 2010 | $1.40 | $0.66 | | | View | N/A | |
| 11/12/2010 | Q3 2010 | $0.30 | $0.74 | | | View | N/A | |
| 8/16/2010 | Q2 2010 | | $0.10 | | | View | N/A | |
| 5/17/2010 | Q1 2010 | | $2.41 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Pernix Therapeutics (NASDAQ:PTX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Pernix Therapeutics (NASDAQ PTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.30%
Institutional Ownership Percentage: 17.05%
Pernix Therapeutics (NASDAQ PTX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/8/2016 | Robert Bruce Reilly | Insider | Sell | 155,000 | $0.06 | $9,300.00 | | |
| 11/4/2016 | Robert Bruce Reilly | Insider | Sell | 45,000 | $0.07 | $3,150.00 | | |
| 8/19/2015 | Sanjay S Patel | CFO | Buy | 5,000 | $4.60 | $23,000.00 | 7,000 | |
| 8/18/2015 | Douglas Drysdale | CEO | Buy | 8,500 | $4.69 | $39,865.00 | 95,161 | |
| 5/6/2015 | Douglas Drysdale | CEO | Buy | 16,000 | $6.40 | $102,400.00 | | |
| 5/6/2015 | Sanjay S Patel | CFO | Buy | 2,000 | $6.42 | $12,840.00 | | |
| 11/3/2014 | Tracy Simmons Clifford | Insider | Sell | 2,246 | $10.00 | $22,460.00 | | |
| 10/28/2014 | Tracy Simmons Clifford | Insider | Sell | 12,754 | $10.00 | $127,540.00 | | |
| 5/21/2014 | James Edward Jr. Smith | major shareholder | Sell | 194,600 | $6.13 | $1,192,898.00 | 3,498,504 | |
| 5/16/2014 | James Edward Jr. Smith | major shareholder | Sell | 310,200 | $6.12 | $1,898,424.00 | 3,693,104 | |
| 5/14/2014 | James Edward Jr. Smith | major shareholder | Sell | 289,400 | $5.47 | $1,583,018.00 | 4,003,304 | |
| 5/9/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $4.37 | $196,650.00 | 4,292,704 | |
| 5/6/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $4.44 | $199,800.00 | 4,337,704 | |
| 5/1/2014 | James Edward Jr. Smith | major shareholder | Sell | 30,000 | $4.68 | $140,400.00 | 4,382,704 | |
| 4/29/2014 | James Edward Jr. Smith | major shareholder | Sell | 30,000 | $4.88 | $146,400.00 | 4,412,704 | |
| 4/25/2014 | James Edward Jr. Smith | major shareholder | Sell | 30,000 | $5.20 | $156,000.00 | 4,442,704 | |
| 4/24/2014 | James Edward Jr. Smith | major shareholder | Sell | 30,000 | $4.94 | $148,200.00 | 4,472,704 | |
| 4/17/2014 | James Edward Jr. Smith | major shareholder | Sell | 20,000 | $4.35 | $87,000.00 | 4,502,704 | |
| 4/15/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $4.63 | $208,350.00 | 4,522,704 | |
| 4/10/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $5.03 | $226,350.00 | 4,567,704 | |
| 4/7/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $4.90 | $220,500.00 | 4,612,704 | |
| 4/2/2014 | Cooper Collins | Insider | Sell | 90,000 | $5.26 | $473,400.00 | 2,500,046 | |
| 4/2/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $5.26 | $236,700.00 | 4,657,704 | |
| 3/28/2014 | James Edward Jr. Smith | major shareholder | Sell | 45,000 | $5.47 | $246,150.00 | 4,702,704 | |
| 3/25/2014 | James Edward Jr. Smith | major shareholder | Sell | 255,000 | $4.21 | $1,073,550.00 | 4,747,704 | |
| 3/4/2014 | Cooper Collins | Insider | Sell | 3,590,000 | $3.40 | $12,206,000.00 | 2,590,046 | |
| 2/5/2014 | Cooper Collins | major shareholder | Sell | 90,000 | $2.22 | $199,800.00 | 6,180,046 | |
| 1/7/2014 | Cooper Collins | major shareholder | Sell | 27,962 | $2.20 | $61,516.40 | 6,270,046 | |
| 1/6/2014 | Cooper Collins | major shareholder | Sell | 62,038 | $2.35 | $145,789.30 | 6,298,008 | |
| 12/6/2013 | Cooper Collins | major shareholder | Sell | 37,452 | $2.31 | $86,514.12 | 6,360,046 | |
| 12/4/2013 | Cooper Collins | major shareholder | Sell | 52,548 | $2.44 | $128,217.12 | 6,397,498 | |
| 11/5/2013 | Cooper C Collins | Major Shareholder | Sell | 90,000 | $2.01 | $180,900.00 | | |
| 10/8/2013 | Cooper Collins | major shareholder | Sell | 23,364 | $2.47 | $57,709.08 | 6,540,046 | |
| 10/9/2012 | Michael Cooper Pearce | Director | Sell | 1,288 | $8.00 | $10,304.00 | | |
(Data available from 1/1/2013 forward)
Pernix Therapeutics (NASDAQ PTX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Contrasting Aptevo Therapeutics (APVO) & Pernix Therapeutics (PTX)
www.americanbankingnews.com - April 23 at 1:42 PM |
 | One Thing To Consider Before Buying Pernix Therapeutics Holdings Inc (NASDAQ:PTX)
finance.yahoo.com - April 11 at 5:01 PM |
 | Form 4/A PERNIX THERAPEUTICS HOLD For: Jan 05 Filed by: Pina Kenneth
www.streetinsider.com - April 10 at 5:02 PM |
 | Active-Investors: Wired News - Amarin's REDUCE-IT Study Reached 100% Mark for Estimated Onset of Targeted Primary MACE
www.finanznachrichten.de - April 6 at 9:03 AM |
| Pernix Therapeutics Announces Return to Market of Zohydro® ER with BeadTek® 20 mg
finance.yahoo.com - March 27 at 9:08 AM |
| Why Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX) Ownership Structure Is Important
finance.yahoo.com - March 20 at 9:04 AM |
| Edited Transcript of PTX earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 8:49 AM |
 | Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 10 at 5:55 PM |
 | Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 ... - Nasdaq
www.nasdaq.com - March 9 at 9:08 AM |
| Earnings Reaction History: Pernix Therapeutics Holdings, Inc., 50.0% Follow-Through Indicator, 12.1% Sensitive - Nasdaq
www.nasdaq.com - March 9 at 9:08 AM |
 | Pernix Therapeutics reports 4Q loss
www.cnbc.com - March 8 at 6:03 PM |
| Pernix Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 6:03 PM |
| Comparing Pernix Therapeutics (PTX) & Akcea Therapeutics (AKCA)
www.americanbankingnews.com - March 8 at 4:13 PM |
| Head to Head Analysis: Pernix Therapeutics (PTX) & Collegium Pharmaceutical (COLL)
www.americanbankingnews.com - March 2 at 1:16 AM |
| Pernix Therapeutics (PTX) to Release Earnings on Thursday
www.americanbankingnews.com - March 1 at 2:08 AM |
| Where Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - February 27 at 5:29 PM |
| Pernix Therapeutics to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 8
finance.yahoo.com - February 22 at 5:15 PM |
 | BRIEF-Pernix Announces Launch Of Authorized Generic Of Treximet
www.reuters.com - February 16 at 4:59 PM |
| Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals
finance.yahoo.com - February 16 at 4:59 PM |
| Head to Head Analysis: Amicus Therapeutics (FOLD) vs. Pernix Therapeutics (PTX)
www.americanbankingnews.com - February 9 at 5:10 AM |
| Pernix Announces Appointment of Lead Independent Director and Key Management Team Promotion
finance.yahoo.com - February 7 at 9:41 AM |
| Reviewing Celsius (CELH) and Pernix Therapeutics (PTX)
www.americanbankingnews.com - February 5 at 11:14 PM |
| Pernix Announces Patent Litigation Settlement Agreement with Actavis Concerning Zohydro® ER
finance.yahoo.com - January 29 at 9:46 AM |
| BRIEF-Pernix Therapeutics Will Reduce Workforce By 41 Employees
www.reuters.com - January 5 at 10:29 AM |
| Pernix Announces Reorganization of Sales Force to Focus on Zohydro® ER with BeadTek™ and Silenor®
finance.yahoo.com - January 5 at 10:29 AM |
| Achaogen's NDA for Plazomicin Gets Priority Review From FDA ... - Nasdaq
www.nasdaq.com - January 3 at 4:39 PM |
 | Achaogen's NDA for Plazomicin Gets Priority Review From FDA
www.zacks.com - January 3 at 9:34 AM |
| Analyzing Celgene (CELG) & Pernix Therapeutics (PTX)
www.americanbankingnews.com - January 2 at 1:20 PM |
| Head-To-Head Survey: AMAG Pharmaceuticals (AMAG) and Pernix Therapeutics (PTX)
www.americanbankingnews.com - January 1 at 11:24 AM |
| ETFs with exposure to Pernix Therapeutics Holdings, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 4:34 PM |
| Analyzing Pernix Therapeutics (PTX) and Concordia International (CXRX)
www.americanbankingnews.com - December 13 at 3:53 PM |
| ETFs with exposure to Pernix Therapeutics Holdings, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 4:48 PM |
| Pernix Therapeutics (PTX) vs. BioLife Solutions (BLFS) Financial Review
www.americanbankingnews.com - November 26 at 5:50 PM |
| BRIEF-Pernix Therapeutics files for mixed shelf offering of up to $150 mln
www.reuters.com - November 23 at 7:51 AM |
| Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 14 at 7:02 AM |
| Platinex Signs LOI to Acquire Interest in Cannabis-Infused Edible Brand and Co-Packing Facility in Oregon, Raising $600,000 in Private Placement - Video Hosted on InvestmentPitch.com
finance.yahoo.com - November 12 at 11:58 AM |
| Pernix Therapeutics Holdings (PTX) and Akorn (AKRX) Financial Analysis
www.americanbankingnews.com - November 10 at 2:14 PM |
| Pernix Therapeutics Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 9 at 11:59 AM |
| Pernix Therapeutics Holdings, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 11:58 AM |
| ETFs with exposure to Pernix Therapeutics Holdings, Inc. : November 7, 2017
finance.yahoo.com - November 9 at 11:58 AM |
| Pernix Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 11:58 AM |
| Edited Transcript of PTX earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 11:58 AM |
| BRIEF-Pernix Therapeutics announces sale of non-core product
www.reuters.com - November 7 at 9:09 AM |
| Pernix Therapeutics (PTX) Sells Non-Core Product for $2M
www.streetinsider.com - November 7 at 9:09 AM |
| Pernix Therapeutics Announces Sale of Non-Core Product
finance.yahoo.com - November 7 at 9:09 AM |
| Who Are The Largest Shareholders In Pernix Therapeutics Holdings Inc (PTX)?
finance.yahoo.com - November 1 at 7:48 AM |
| Pernix Therapeutics Holdings, Inc. (PTX) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - November 1 at 1:44 AM |
| Pernix Therapeutics to Report Third Quarter 2017 Financial Results on Tuesday, November 7
finance.yahoo.com - October 27 at 11:55 AM |
| Analyzing Pernix Therapeutics Holdings (PTX) and CoLucid Pharmaceuticals (CLCD)
www.americanbankingnews.com - October 25 at 2:54 PM |
| BRIEF-Pernix Therapeutics says CFO and president Graham Miao resigns
www.reuters.com - October 18 at 2:22 AM |
Pernix Therapeutics (NASDAQ:PTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Pernix Therapeutics (NASDAQ:PTX) Income Statement, Balance Sheet and Cash Flow Statement
Pernix Therapeutics (NASDAQ PTX) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
